This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gaymes, T. J. Articles by Rassool, F. V. Search for Related Content PubMed PubMed Citation Articles by Gaymes, T. J. Articles by Rassool, F. V.

Myeloid Leukemias Have Increased Activity of the Nonhomologous End-Joining Pathway and Concomitant DNA Misrepair that Is Dependent on the Ku70/86 Heterodimer

Department of Haematological Medicine, Leukaemic Sciences Laboratories, The Rayne Institute, GKT School of Medicine, Denmark Hill, London SE5 9NU

Human myeloid leukemias are characterized by chromosomal abnormalities, including translocations, deletions, and allelic loss. These alterations are known to disrupt the function of genes that contribute to tumor initiation and progression. The mechanism underlying the appearance of these chromosomal alterations is poorly understood. Recent evidence suggests that altered nonhomologous end joining (NHEJ) is associated with the incidence of chromosome abnormalities in mutant rodent cells. This pathway is thought to provide a major mechanism for the repair of double-strand breaks (DSB) in higher eukaryotes. Here, we show that in an in vitro assay for DSB end ligation, nuclear extracts prepared from cultured and primary myeloid leukemia cells show a 2–7-fold increase in end-ligation efficiency as compared with mobilized peripheral CD34+ blood progenitor cells (CD34+) and interleukin-2-stimulated peripheral blood lymphocytes from normal healthy donors (P < 0.001). Furthermore, using an in vitro plasmid LacZ gene reactivation assay to determine DSB repair fidelity, nuclear extracts prepared from myeloid leukemia cells showed an increased frequency of misrepair compared with normal control cells (P < 0.001). Most importantly, this misrepair in myeloid leukemia cells is associated with large deletions (30–400 bp) within the test plasmids used in our assay. These deletions were not observed using normal hematopoietic cells (<28 bp). Strikingly, we show that the NHEJ proteins, Ku70 and 86, are required for the deletions in myeloid leukemias because preincubating nuclear extracts from leukemic cells with antisera against Ku86 and Ku70 inhibits plasmid reactivation and restores the frequency and size of deletions to control levels. Our findings suggest that an overactive NHEJ system and, specifically, aberrant Ku70/86 activity is a candidate mechanism for chromosomal instability in myeloid leukemias.

This article has been cited by other articles:

				A. Sallmyr, J. Fan, K. Datta, K.-T. Kim, D. Grosu, P. Shapiro, D. Small, and F. Rassool Internal tandem duplication of FLT3 (FLT3/ITD) induces increased ROS production, DNA damage, and misrepair: implications for poor prognosis in AML Blood, March 15, 2008; 111(6): 3173 - 3182. [Abstract] [Full Text] [PDF]

				F. V. Rassool, T. J. Gaymes, N. Omidvar, N. Brady, S. Beurlet, M. Pla, M. Reboul, N. Lea, C. Chomienne, N. S.B. Thomas, et al. Reactive Oxygen Species, DNA Damage, and Error-Prone Repair: A Model for Genomic Instability with Progression in Myeloid Leukemia? Cancer Res., September 15, 2007; 67(18): 8762 - 8771. [Abstract] [Full Text] [PDF]

				L. Rink, A. Slupianek, T. Stoklosa, M. Nieborowska-Skorska, K. Urbanska, I. Seferynska, K. Reiss, and T. Skorski Enhanced phosphorylation of Nbs1, a member of DNA repair/checkpoint complex Mre11-RAD50-Nbs1, can be targeted to increase the efficacy of imatinib mesylate against BCR/ABL-positive leukemia cells Blood, July 15, 2007; 110(2): 651 - 660. [Abstract] [Full Text] [PDF]

				L.-I. Lin, C.-Y. Chen, D.-T. Lin, W. Tsay, J.-L. Tang, Y.-C. Yeh, H.-L. Shen, F.-H. Su, M. Yao, S.-Y. Huang, et al. Characterization of CEBPA Mutations in Acute Myeloid Leukemia: Most Patients with CEBPA Mutations Have Biallelic Mutations and Show a Distinct Immunophenotype of the Leukemic Cells Clin. Cancer Res., February 15, 2005; 11(4): 1372 - 1379. [Abstract] [Full Text] [PDF]

				J. D. Licht and D. W. Sternberg The Molecular Pathology of Acute Myeloid Leukemia Hematology, January 1, 2005; 2005(1): 137 - 142. [Abstract] [Full Text] [PDF]

				J. H. Um, J. K. Kwon, C.-D. Kang, M. J. Kim, D. S. Ju, J. H. Bae, D. W. Kim, B. S. Chung, and S. H. Kim Relationship between Antiapoptotic Molecules and Metastatic Potency and the Involvement of DNA-Dependent Protein Kinase in the Chemosensitization of Metastatic Human Cancer Cells by Epidermal Growth Factor Receptor Blockade J. Pharmacol. Exp. Ther., December 1, 2004; 311(3): 1062 - 1070. [Abstract] [Full Text] [PDF]

				M. O. Nowicki, R. Falinski, M. Koptyra, A. Slupianek, T. Stoklosa, E. Gloc, M. Nieborowska-Skorska, J. Blasiak, and T. Skorski BCR/ABL oncogenic kinase promotes unfaithful repair of the reactive oxygen species-dependent DNA double-strand breaks Blood, December 1, 2004; 104(12): 3746 - 3753. [Abstract] [Full Text] [PDF]

				N. K. Sah, A. Munshi, T. Nishikawa, T. Mukhopadhyay, J. A. Roth, and R. E. Meyn Adenovirus-mediated wild-type p53 radiosensitizes human tumor cells by suppressing DNA repair capacity Mol. Cancer Ther., November 1, 2003; 2(11): 1223 - 1231. [Abstract] [Full Text] [PDF]

				Y. Canitrot, R. Falinski, T. Louat, G. Laurent, C. Cazaux, J.-S. Hoffmann, D. Lautier, and T. Skorski p210 BCR/ABL kinase regulates nucleotide excision repair (NER) and resistance to UV radiation Blood, October 1, 2003; 102(7): 2632 - 2637. [Abstract] [Full Text] [PDF]

				M. Libura, V. Asnafi, A. Tu, E. Delabesse, I. Tigaud, F. Cymbalista, A. Bennaceur-Griscelli, P. Villarese, G. Solbu, A. Hagemeijer, et al. FLT3 and MLL intragenic abnormalities in AML reflect a common category of genotoxic stress Blood, September 15, 2003; 102(6): 2198 - 2204. [Abstract] [Full Text] [PDF]

				N. Brady, T. J. Gaymes, M. Cheung, G. J. Mufti, and F. V. Rassool Increased Error-prone NHEJ Activity in Myeloid Leukemias Is Associated with DNA Damage at Sites that Recruit Key Nonhomologous End-Joining Proteins Cancer Res., April 15, 2003; 63(8): 1798 - 1805. [Abstract] [Full Text] [PDF]